TIDMHIK

RNS Number : 3273V

Hikma Pharmaceuticals Plc

23 July 2018

London, 23 July 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the multinational generic pharmaceutical company, will announce its interim financial results for the six months ended 30 June 2018 on Wednesday 15 August 2018.

A presentation and webcast for analysts will be held at 9.30am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 9.15am.

To join via conference call please dial:

UK Toll Free Number: 020 3936 2999

US Toll Free Number: 1 855 9796 654

Standard International Access: +44 20 3936 2999

Password: 911652

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://webcast.openbriefing.com/hikma_interim_results_2018/.

Playback facility:

A playback of the conference call will be available after the presentation.

United Kingdom - 020 3936 3001

United States - 1 845 709 8569

All other locations - + 44 20 3936 3001

Replay code: 338668

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

 
 Susan Ringdal 
  VP Corporate Strategy and Director    +44 (0)20 7399 2760/ +44 7776 
  of Investor Relations                  477050 
 Virginia Spring                        +44 (0)20 3892 4389/ +44 7973 
  Investor Relations Manager             679502

FTI Consulting

 
 Ben Atwell/Brett Pollard    +44 (0)20 3727 1000

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORGMGZNMGVGRZM

(END) Dow Jones Newswires

July 23, 2018 04:00 ET (08:00 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Hikma Pharmaceuticals Charts.